The information provided on this website is intended expressly for healthcare professionals within the US
Please select one of the following:
You are not authorized to access this page.
©2024 Bayer. All rights reserved. BAYER, the Bayer Cross, and KERENDIA are registered trademarks of Bayer. All other trademarks are the property of their respective owners. Last updated 01/24
You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
hidden link for autofocus
References:
- American Diabetes Association (Section 10. Cardiovascular disease and risk management: standards of medical care in diabetes). Diabetes Care. 2023;46(Suppl1): S158-S190. doi:10.2337/dc23-S010.
- American Diabetes Association (Section 11: Chronic kidney disease and risk management: standards of care in diabetes). Diabetes Care. 2023;46(Suppl1):S191-S202. doi:/10.2337/dc23-S011.
- Agarwal R, et al. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777.
- Bakris GL, et al; FIDELIO-DKD Investigators. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845.
- Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline—2022 Update. Endocr Pract. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002.
- Data on file, Bayer.
- de Boer IH, et al. Diabetes Care. 2022;45(12):3075-3090. doi:10.2337/dci22-0027.
- Fox CS, et al. Lancet. 2012;380(9854):1662-1673. doi:10.1016/S0140-6736(12)61350-6. (Published correction appears in Lancet. 2013;381(9864):374.)
- Inoue K, et al. Ann Epidemiol. 2021;55:15-23. doi:10.1016/j.annepidem.2020.12.004.
- KDIGO—Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Intl Suppl. 2013;3(1):1-150. doi:10.1038/kisup.2012.73.
- KDIGO—Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1-115. doi:10.1016/j.kint.2020.06.019.
- KDIGO—Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2022;102(5S):S1-S127. doi:10.1016/j.kint.2022.06.008.
- KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; September 2022.
- Kolkhof P, et al. Pharmacol Res. 2021;172:105859. doi:10.1016/j.phrs.2021.105859.
- Pasternak M, et al. JAMA Netw Open. 2022;5(8):e2225821. doi:10.1001/jamanetworkopen.2022.25821.
- Pitt B, et al. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956.
- Rossing P, et al. Am J Med. 2022;135(5):576-580. doi:10.1016/j.amjmed.2021.11.019.